RepliCel Life Sciences Inc. is a regenerative medicine company focused on developing autologous cell therapies that treat functional cellular deficits. The diseases being addressed are chronic tendinosis, skin aging, and androgenetic alopecia (pattern baldness). Each disease state is consistent with a deficit of a specific cell type, which the Company believes is critical to normal function. All treatments under development are based on the Company's technology, which utilizes cells isolated from a patient's own healthy hair follicles. These products are built on the Company's manufacturing platforms and are covered by issued and filed patents, as well as trade secrets. The Company is also developing a programmable injector device designed for dermal injections of cells as currently approved dermal filler products.